We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases

By LabMedica International staff writers
Posted on 07 Jul 2025

The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. More...

These gut bacteria produce a variety of metabolites that act as molecular messengers, influencing processes such as metabolism, immune function, brain activity, and mood. However, understanding the exact relationships between bacteria and the metabolites they produce is still in its infancy.

As gut bacteria are highly diverse and interact in complex ways, it’s challenging to pinpoint how these microbes influence human health and diseases. The difficulty in mapping these relationships hinders the development of targeted treatments. Researchers have been seeking methods to better understand the bacteria-metabolite interactions and how they can be applied in personalized treatments. Now, for the first time, researchers have used a special kind of artificial intelligence (AI) to probe a dataset on gut bacteria in order to find relationships that current analytical tools could not reliably identify.

The tool called VBayesMM has been developed by a team of researchers from the University of Tokyo (Tokyo, Japan) to help map the complex relationships between gut bacteria and metabolites. Using a Bayesian neural network, VBayesMM analyzes large datasets to identify key bacterial players affecting metabolite production. The system automatically distinguishes between the significant bacteria that influence metabolites and the vast background of less relevant microbes.

VBayesMM also accounts for uncertainty in the predictions, providing more accurate and reliable results compared to other existing methods. The tool has been tested on real data from studies on sleep disorders, obesity, and cancer, consistently outshining other techniques and uncovering bacterial families linked with known biological processes.

The findings, published in Nature Communications, show that the tool outperformed existing analytical methods by reliably identifying bacteria which align with biological processes and by acknowledging uncertainty in predictions. This approach gives researchers greater confidence in the results, reducing the risk of overconfident and potentially incorrect conclusions.

The tool offers promising applications in personalized healthcare, where it could help identify bacterial targets for treatments or dietary interventions. Moving forward, the researchers plan to enhance VBayesMM by incorporating more comprehensive chemical datasets and improving its robustness for diverse patient populations, ultimately transitioning from basic research to practical medical applications.

“The problem is that we’re only beginning to understand which bacteria produce which human metabolites and how these relationships change in different diseases,” said Project Researcher Tung Dang from the Tsunoda lab in the Department of Biological Sciences. “By accurately mapping these bacteria-chemical relationships, we could potentially develop personalized treatments. Imagine being able to grow a specific bacterium to produce beneficial human metabolites or designing targeted therapies that modify these metabolites to treat diseases.”

Related Links:
University of Tokyo


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Urine samples can indicate lupus nephritis without the need for repeat and painful renal biopsies (Photo courtesy of Shutterstock)

Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients

Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. Among the five million people living with lupus globally, nearly half develop lupus nephritis,... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.